Downregulated formyl peptide receptor 2 expression in the epileptogenic foci of patients with focal cortical dysplasia type IIb and tuberous sclerosis complex

Focal cortical dysplasia type IIb (FCDIIb) and tuberous sclerosis complex (TSC) show persistent neuroinflammation, which promotes epileptogenesis and epilepsy progression, suggesting that endogenous resolution of inflammation is inadequate to relieve neuronal network hyperexcitability. To explore the potential roles of formyl peptide receptor 2 (FPR2), which is a key regulator of inflammation resolution, in epilepsy caused by FCDIIb and TSC, we examined the expression and cellular distribution of FPR2.

[1]  M. Marín-Gracia,et al.  Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies , 2022, Biomedicines.

[2]  Pravin S. Shirude,et al.  Formyl peptide receptor 2 and heart disease. , 2022, Seminars in immunology.

[3]  Anwen Shao,et al.  The Role of Formyl Peptide Receptors in Neurological Diseases via Regulating Inflammation , 2021, Frontiers in Cellular Neuroscience.

[4]  E. Lacivita,et al.  Time-Dependent Protective and Pro-Resolving Effects of FPR2 Agonists on Lipopolysaccharide-Exposed Microglia Cells Involve Inhibition of NF-κB and MAPKs Pathways , 2021, Cells.

[5]  Xiao Ke,et al.  The mechanism of Annexin A1 to modulate TRPV1 and nociception in dorsal root ganglion neurons , 2021, Cell & bioscience.

[6]  J. Lünemann,et al.  Targeting Inflammasomes to Treat Neurological Diseases , 2021, Annals of neurology.

[7]  S. Landi,et al.  Neuroinflammation: A Signature or a Cause of Epilepsy? , 2021, International journal of molecular sciences.

[8]  E. Lacivita,et al.  The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Exhibits Anti-Inflammatory Activity in LPS-Stimulated Organotypic Hippocampal Cultures , 2021, Cells.

[9]  Tao Wang,et al.  Annexin A1 protects against cerebral ischemia–reperfusion injury by modulating microglia/macrophage polarization via FPR2/ALX-dependent AMPK-mTOR pathway , 2021, Journal of neuroinflammation.

[10]  Hui Yang,et al.  Abnormal Rat Cortical Development Induced by Ventricular Injection of rHMGB1 Mimics the Pathophysiology of Human Cortical Dysplasia , 2021, Frontiers in Cell and Developmental Biology.

[11]  P. Kubes,et al.  Targeting AnxA1/Fpr2/ALX Pathway Regulates Neutrophil Function Promoting Thrombo-Inflammation Resolution in Sickle Cell Disease. , 2021, Blood.

[12]  E. Brennan,et al.  Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential. , 2021, European journal of medicinal chemistry.

[13]  Ling-Yun Wu,et al.  Resolvin D1 Attenuates Innate Immune Reactions in Experimental Subarachnoid Hemorrhage Rat Model , 2021, Molecular Neurobiology.

[14]  Xiaotang Fan,et al.  Downregulated GPR30 expression in the epileptogenic foci of female patients with focal cortical dysplasia type IIb and tuberous sclerosis complex is correlated with 18F‐FDG PET‐CT values , 2020, Brain pathology.

[15]  Xietong Wang,et al.  Effect of RvD1/FPR2 on inflammatory response in chorioamnionitis , 2020, Journal of cellular and molecular medicine.

[16]  M. Perretti,et al.  Formyl peptide receptor type 2 agonists to kick‐start resolution pharmacology , 2020, British journal of pharmacology.

[17]  C. Hang,et al.  Functions of resolvin D1-ALX/FPR2 receptor interaction in the hemoglobin-induced microglial inflammatory response and neuronal injury , 2020, Journal of Neuroinflammation.

[18]  J. Dvorak,et al.  Serum amyloid A is a soluble pattern recognition receptor that drives type 2 immunity , 2020, Nature Immunology.

[19]  Yi Yao,et al.  Resective epilepsy surgery in tuberous sclerosis complex: a nationwide multicentre retrospective study from China. , 2020, Brain : a journal of neurology.

[20]  Zhiyuan Zhang,et al.  Resolvin D1 ameliorates cognitive impairment following traumatic brain injury via protecting astrocytic mitochondria. , 2020, Journal of neurochemistry.

[21]  E. Lacivita,et al.  The Contribution of Formyl Peptide Receptor Dysfunction to the Course of Neuroinflammation: A Potential Role in the Brain Pathology , 2020, Current neuropharmacology.

[22]  John H. Zhang,et al.  RvD1binding with FPR2 attenuates inflammation via Rac1/NOX2 pathway after neonatal hypoxic-ischemic injury in rats , 2019, Experimental Neurology.

[23]  C. Bulteau,et al.  Dissecting the genetic basis of focal cortical dysplasia: a large cohort study , 2019, Acta Neuropathologica.

[24]  A. Vezzani,et al.  Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy , 2019, Nature Reviews Neurology.

[25]  S. Czuczwar,et al.  An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs , 2019, Expert opinion on drug safety.

[26]  John H. Zhang,et al.  Annexin A1 attenuates neuroinflammation through FPR2/p38/COX‐2 pathway after intracerebral hemorrhage in male mice , 2019, Journal of neuroscience research.

[27]  J. Isnard,et al.  Malformations of cortical development: New surgical advances. , 2019, Revue neurologique.

[28]  E. Aronica,et al.  n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis , 2018, Brain : a journal of neurology.

[29]  A. Rabinowicz,et al.  The differential effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on seizure frequency in patients with drug-resistant epilepsy — A randomized, double-blind, placebo-controlled trial , 2018, Epilepsy & Behavior.

[30]  W. Ong,et al.  Localisation of Formyl-Peptide Receptor 2 in the Rat Central Nervous System and Its Role in Axonal and Dendritic Outgrowth , 2018, Neurochemical Research.

[31]  Hui Yang,et al.  TRIF contributes to epileptogenesis in temporal lobe epilepsy during TLR4 activation , 2018, Brain, Behavior, and Immunity.

[32]  Ming Liu,et al.  Upregulation of HMGB1-TLR4 inflammatory pathway in focal cortical dysplasia type II , 2018, Journal of Neuroinflammation.

[33]  J. H. Cross,et al.  Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology , 2017, Epilepsia.

[34]  D. Lett,et al.  Extended post-mortem delay times should not be viewed as a deterrent to the scientific investigation of human brain tissue: a study from the Brains for Dementia Research Network Neuropathology Study Group, UK , 2016, Acta Neuropathologica.

[35]  Mingyong Liu,et al.  Formylpeptide Receptors Promote the Migration and Differentiation of Rat Neural Stem Cells , 2016, Scientific Reports.

[36]  D. Granger,et al.  Formyl-Peptide Receptor 2/3/Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease , 2016, Circulation.

[37]  W. Guo,et al.  Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex , 2016, Journal of Neuroinflammation.

[38]  Pavel Krsek,et al.  Specific pattern of maturation and differentiation in the formation of cortical tubers in tuberous sclerosis omplex (TSC): evidence from layer-specific marker expression , 2016, Journal of Neurodevelopmental Disorders.

[39]  Robert B. Petersen,et al.  Individual Case Analysis of Postmortem Interval Time on Brain Tissue Preservation , 2016, PloS one.

[40]  John H. Zhang,et al.  Lipoxin A4 Reduces Inflammation Through Formyl Peptide Receptor 2/p38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats , 2016, Stroke.

[41]  L. Lauritzen,et al.  DHA Effects in Brain Development and Function , 2016, Nutrients.

[42]  S. Gabriel,et al.  Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome , 2015, Nature Genetics.

[43]  C. Cepeda,et al.  Basic Mechanisms of Epileptogenesis in Pediatric Cortical Dysplasia , 2015, CNS neuroscience & therapeutics.

[44]  R. Kuzniecky.  Epilepsy and malformations of cortical development: new developments. , 2015, Current opinion in neurology.

[45]  J. Gleeson,et al.  Pathogenetic mechanisms of focal cortical dysplasia , 2014, Epilepsia.

[46]  E. Aronica,et al.  Fetal brain mTOR signaling activation in tuberous sclerosis complex. , 2014, Cerebral cortex.

[47]  E. Aronica,et al.  Cell injury and Premature Neurodegeneration in Focal Malformations of Cortical Development , 2014, Brain pathology.

[48]  James W Ironside,et al.  Brain banking for neurological disorders , 2013, The Lancet Neurology.

[49]  R. Ammendola,et al.  Distinct Signaling Cascades Elicited by Different Formyl Peptide Receptor 2 (FPR2) Agonists , 2013, International journal of molecular sciences.

[50]  P. V. van Rijen,et al.  Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. , 2011, Brain : a journal of neurology.

[51]  S. Yoo,et al.  Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti‐nociception , 2010, British journal of pharmacology.

[52]  K. Stuhlmeier,et al.  The TSC-mTOR signaling pathway regulates the innate inflammatory response. , 2008, Immunity.

[53]  Carol A. Tamminga,et al.  Human postmortem tissue: What quality markers matter? , 2006, Brain Research.

[54]  P. Dodd,et al.  Biochemical and molecular studies using human autopsy brain tissue , 2003, Journal of neurochemistry.